Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_assertion type Assertion NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_head.
- NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_assertion wasGeneratedBy ECO_0000203 NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_provenance.
- NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_assertion wasDerivedFrom befree-20150227 NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_provenance.
- NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_assertion SIO_000772 17848408 NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_provenance.
- NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_assertion evidence source_evidence_literature NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_provenance.
- NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_assertion description "[Nevertheless, overexpression of Bcl-2 may result in 'oncogene addiction' of the cancer cell, which can be exploited by using BH3-domain inhibitors alone or in combination with other agents, including conventional chemotherapeutics (such as doxorubicin) or novel targeted therapies (such as the proteasome inhibitor bortezomib), for the treatment of aggressive thyroid cancer, including the medullary and anaplastic types.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_provenance.